Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical, with a valuation of $80 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $3 million. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, intellectual property advancement, and operating expenses.
Sen-Jam Pharmaceutical, with a valuation of $80 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $150,000 and a maximum target of $3 million. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, intellectual property advancement, and operating expenses.
Stay in the Loop
Get updates from Sen-Jam Pharmaceutical
Get exclusive updates from Sen-Jam Pharmaceutical
Be the first to know about company milestones, news, and opportunities.
🔒 No spam. Just real progress.
Company Stats
Key metrics about Sen-Jam Pharmaceutical
Are you the owner of Sen-Jam Pharmaceutical?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company